Effects of statins on the recovery of olfactory function in a 3-methylindole-induced anosmia mouse model

American Journal of Rhinology and Allergy

Volumn 26, Issue 2, 2012, Pages

  Kim, Hyo Yeol ^a   Kim, Joon Ho ^a   Dhong, Hun Jong ^a   Kim, Ki Ryung ^a   Chung, Seung Kyu ^a   Chung, Soo Chan ^b   Kang, Jeong Min ^c   Jung, Yong Gi ^a   Jang, Seong Yun ^a   Hong, Sang Duk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

^c Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLFACTORY MARKER PROTEIN; SKATOLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOSMIA; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMELLING; STOMACH TUBE; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, INBRED BALB C; OLFACTION DISORDERS; PARANASAL SINUSES; PYRROLES; RECOVERY OF FUNCTION; SKATOLE; SMELL;

EID: 84860118492     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3719     Document Type: Article

References (30)

1. Smith WM, Davidson TM, and Murphy C. Toxin-induced chemosensory dysfunction: A case series and review. Am J Rhinol Allergy 23:578-581, 2009.
2. Bramerson A, Johansson L, Ek L, et al. Prevalence of olfactory dysfunction: The Skovde population-based study. Laryngoscope 114: 733-737, 2004. (Pubitemid 38548788)
3. Cullen MM, and Leopold DA. Disorders of smell and taste. Med Clin North Am 83:57-74, 1999. (Pubitemid 29031691)
4. Temmel AF, Quint C, Schickinger-Fischer B, et al. Characteristics of olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg 128:635-641, 2002. (Pubitemid 34665843)
5. Cowart BJ, Young IM, Feldman RS, and Lowry LD. Clinical disorders of smell and taste. Occup Med 12:465-483, 1997. (Pubitemid 127795106)
6. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24:1454-1459, 2004. (Pubitemid 39050440)
7. Jung KH, Chu K, Jeong SW, et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 35:1744-1749, 2004. (Pubitemid 38823658)
8. Sarkey JP, Richards MP, and Stubbs EB Jr. Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. J Neurochem 100:1265-1277, 2007.
9. Kim HY, Dhong HJ, Min JY, et al. Effects of statins on regeneration of olfactory epithelium. Am J Rhinol Allergy 24:121-125, 2010.
10. Kim JW, Hong SL, Lee CH, et al. Relationship between olfactory function and olfactory neuronal population in C57BL6 mice injected intraperitoneally with 3-methylindole. Otolaryngol Head Neck Surg 143:837-842, 2010.
11. Dhong HJ, Kim HY, and Ha BS. Histologic changes to olfactory epithelium in hypothyroid rats. Otolaryngol Head Neck Surg 129:24-32, 2003. (Pubitemid 37391040)
12. Bray TM, and Kubow S. Involvement of free radicals in the mechanism of 3-methylindole-induced pulmonary toxicity: An example of metabolic activation in chemically induced lung disease. Environ Health Perspect 64:61-67, 1985. (Pubitemid 16135779)
13. Lee CH, Mo JH, Shim SH, et al. Effect of ginkgo biloba and dexamethasone in the treatment of 3-methylindole-induced anosmia mouse model. Am J Rhinol 22:292-296, 2008. (Pubitemid 351846811)
14. Peele DB, Allison SD, Bolon B, et al. Functional deficits produced by 3-methylindole-induced olfactory mucosal damage revealed by a simple olfactory learning task. Toxicol Appl Pharmacol 107:191-202, 1991.
15. Turk MA, Henk WG, and Flory W. 3-Methylindole-induced nasal mucosal damage in mice. Vet Pathol 24:400-403, 1987.
16. Miller MA, and O'Bryan MA. Ultrastructural changes and olfactory deficits during 3-methylindole-induced olfactory mucosal necrosis and repair in mice. Ultrastruct Pathol 27:13-21, 2003. (Pubitemid 36293151)
17. Setzer AK, and Slotnick B. Disruption of axonal transport from olfactory epithelium by 3-methylindole. Physiol Behav 65:479-487, 1998. (Pubitemid 29015764)
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
19. Seyfried D, Han Y, Lu D, et al. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 101:104-107, 2004. (Pubitemid 38808468)
20. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53:743-751, 2003. (Pubitemid 36622511)
21. Stanislaus R, Singh AK, and Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66:155-162, 2001. (Pubitemid 32912284)
22. Stanislaus R, Gilg AG, Singh AK, and Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 333:167-170, 2002. (Pubitemid 35335769)
23. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995.
24. Pan HC, Yang DY, Ou YC, et al. Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury. Neurosurgery 67:376-388, 2010.
25. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312:786-793, 2005. (Pubitemid 40189580)
26. Schmechel A, Grimm M, El-Armouche A, et al. Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc Res 82:100-106, 2009.
27. Stevens MH. Steroid-dependent anosmia. Laryngoscope 111:200-203, 2001. (Pubitemid 32142823)
28. Martignoni M, Groothuis GM, and de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894, 2006. (Pubitemid 44911538)
29. Stevens JC, Shipley LA, Cashman JR, et al. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab Dispos 21:753-760, 1993. (Pubitemid 23298435)
30. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58, 1997. (Pubitemid 27438945)